title: Adaptive cytoprotection against deoxycholate-induced injury in human gastric cells in vitro: is there a role for endogenous prostaglandins?
abstract: The majority of previous work investigating adaptive cytoprotection has involved in vivo studies, which have suggested that this protective response is in large part mediated by endogenous prostaglandins (PGs). The aim of this study was to investigate adaptive cytoprotection under in vitro conditions in human gastric cells and to better delineate the role of endogenous PGs in this protective response. AGS cells (a human gastric carcinoma cell line) were characterized morphologically and subsequently used for all experiments. Sodium deoxycholate was used as both the mild irritant and the damaging agent, and cell injury was quantified using both a commercial viability/cytotoxicity kit as well as transepithelial permeability studies. Finally, endogenous PG synthesis in response to varying concentrations of deoxycholate was determined. AGS cells were determined to be morphologically similar to gastric mucous cells. Pretreatment of cells with low-dose deoxycholate significantly attenuated injury upon subsequent exposure to damaging concentrations of deoxycholate, and this protection was determined to be dependent upon both concentration and duration of mild irritant exposure. Preincubation of AGS cells with indomethacin reversed protection induced by mild irritant pretreatment and also significantly increased cellular susceptibility to injury. Results of the permeability studies closely paralleled those assessing cell mortality. While deoxycholate exposure increased PG synthesis, the concentrations required were much higher than those needed to initiate protection. Adaptive cytoprotection exists in AGS cells under in vitro conditions independent of intact blood flow, neural innervation, or circulating humoral mediators. While this protection is reversed by indomethacin, it appears that this reversal results from increased cellular injury secondary to diminished basal PGs, rather than inhibition of endogenous PG synthesis.
authors.affiliation: Theodore Cooper Surgical Research Institute, Department of Surgery, Saint Louis University Health Sciences Center, Missouri 63104, USA.
authors.forename: E R
authors.initials: ER
authors.lastname: Kokoska
authors.forename: G S
authors.initials: GS
authors.lastname: Smith
authors.forename: C L
authors.initials: CL
authors.lastname: Rieckenberg
authors.forename: Y
authors.initials: Y
authors.lastname: Deshpande
authors.forename: A
authors.initials: A
authors.lastname: Banan
authors.forename: T A
authors.initials: TA
authors.lastname: Miller
mesh_terms: D002463:Cell Membrane Permeability / Q000187:drug effects; D002470:Cell Survival; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D019610:Cytoprotection / Q000502:physiology*; D003840:Deoxycholic Acid / Q000633:toxicity*; D015232:Dinoprostone / Q000502:physiology; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D011453:Prostaglandins / Q000502:physiology*; D014407:Tumor Cells, Cultured / Q000187:drug effects*
chemical_list: D016861:Cyclooxygenase Inhibitors; D011453:Prostaglandins; D003840:Deoxycholic Acid; D015232:Dinoprostone; D007213:Indomethacin